Can we catch the second loach employing BACE1 inhibition, even as the first one might be escaping?

Abstract

Obesity, diabetes, and Alzheimer's disease (AD) are becoming increasingly common, especially in the aging population, and are adversely affecting quality of life for patients and their families. These conditions have been shown to be interrelated, and AD has recently been referred to as type 3 diabetes, because neuronal insulin resistance underlies the pathophysiology of AD. Based on the amyloid-beta hypothesis, BACE1 (β-site amyloid precursor protein-cleaving enzyme 1) is the most promising drug target for AD. BACE1 is a β-secretase that processes the amyloid precursor protein (APP) to generate amyloid β-42 (Aβ42).